Overview
Definition and Classification
Gliomas are a type of tumor that originates from glial cells, which are non-neuronal cells that provide support and protection for neurons in the brain and spinal cord. They represent the most common type of primary brain tumor, accounting for approximately 30% to 40% of all intracranial tumors, with glioblastomas being the most prevalent subtype among adults, constituting about half of all gliomas.[3.1]
The classification of gliomas has evolved significantly, particularly with the introduction of molecular genetic profiling. Historically, gliomas were classified primarily based on histopathological criteria; however, the World Health Organization (WHO) updated its classification system in 2016 to incorporate molecular biomarkers, such as IDH mutations and 1p/19q codeletion, which are crucial for accurate diagnosis and prognosis.[37.1] This shift towards molecular classification allows for a more nuanced understanding of glioma subtypes, which can be categorized into low-grade, atypical/anaplastic, or high-grade tumors based on cell morphology, mitotic activity, and specific molecular markers.[4.1]
Furthermore, advancements in genome-wide molecular profiling have revealed characteristic genetic alterations and epigenetic profiles associated with different glioma types. These molecular characteristics not only refine glioma classification but also enhance the prediction of patient outcomes and guide individualized treatment strategies.[40.1] As research continues, it is anticipated that the classification of gliomas will further evolve, leading to the identification of additional subtypes and a deeper understanding of the genetic heterogeneity present within these tumors.[38.1]
Types of Gliomas
Gliomas are a diverse group of brain tumors that originate from glial cells, which include astrocytes, oligodendrocytes, and ependymal cells. Among the various types of gliomas, astrocytomas are the most prevalent, arising from astrocytes that clean the brain's environment and support neuronal function. Astrocytomas can be classified into different subtypes and grades, with Grade IV astrocytoma, commonly known as glioblastoma, being the most invasive and aggressive form.[8.1]
Genetic markers play a crucial role in categorizing gliomas and influencing their behavior and treatment responses. For instance, the presence of an isocitrate dehydrogenase (IDH) mutation is associated with a less aggressive tumor phenotype and improved patient survival rates. This mutation is identified in over 80% of World Health Organization (WHO) grade II and III gliomas, and it is also frequently found in secondary glioblastomas.[19.1] Additionally, the co-deletion of chromosomal arms 1p and 19q is another genetic alteration that indicates a more favorable response to chemotherapy.[18.1]
The classification of gliomas is essential for determining appropriate treatment strategies and prognostic outcomes, highlighting the importance of understanding the specific genetic and histological characteristics of these tumors.
History
Early Discoveries
The first recorded observations of gliomas date back to the early 19th century, with significant contributions from researchers such as Berns in 1800 and Abernety in 1804. The comprehensive histomorphological description of gliomas was later provided by Rudolf Virchow in 1865, marking a pivotal moment in the understanding of these tumors.[48.1]
In the 1920s, Percival Bailey and Harvey Cushing made substantial advancements in glioma classification. Their seminal study published in 1925 analyzed over 400 gliomas and established a four-tiered grading system that correlated histological and anatomical properties of gliomas with patient outcomes. This classification laid the groundwork for modern diagnostic criteria and treatment approaches.[52.1] The insights gained from their work were prescient, as they drew parallels between the histological appearances of glial tumors and the developmental stages of glia, which significantly influenced the understanding of glioma subtypes.[51.1]
The World Health Organization (WHO) later adopted and refined these classifications in 2016, describing gliomas as tumors arising from glia, the supportive cells of the central nervous system. This evolution in classification reflects the ongoing advancements in histopathology and the need for precise diagnostic criteria in the management of gliomas.[49.1] Overall, the early discoveries and classifications have been foundational in shaping contemporary glioma research and treatment strategies.[47.1]
Evolution of Treatment Approaches
Advancements in the treatment of gliomas have evolved significantly over the years, particularly with the integration of advanced imaging technologies and a deeper understanding of the molecular biology of these tumors. Historically, the outcomes for glioblastoma patients improved incrementally from the time of Harvey Cushing, primarily due to advancements in localization, imaging, anesthesia, surgical techniques, and the management of cerebral edema. However, a pivotal moment occurred in the 1990s with the introduction of magnetic resonance imaging (MRI), which enabled better degrees of tumor resection and significantly influenced surgical approaches to glioma treatment.[53.1]
Modern MRI techniques, including diffusion-weighted imaging and functional MRI, have become essential in diagnosing and managing gliomas, the most prevalent primary brain tumors.[54.1] These advanced imaging modalities not only enhance the visualization of tumor characteristics but also allow for a more precise assessment of intra- and intertumoral heterogeneity, which is crucial for tailoring treatment strategies.[55.1] The necessity for greater standardization and collaborative research in utilizing MRI's full potential has been emphasized, advocating for a more profound understanding of glioma biology to improve personalized therapy.[56.1]
Intraoperative imaging technologies, such as intraoperative MRI (iMRI), functional MRI (fMRI), and diffusion tensor imaging (DTI), have also emerged as game-changers in glioma surgery. These modalities help mitigate the effects of brain shift during surgery, thereby maximizing safe resection margins and improving postoperative outcomes.[57.1] Additionally, intraoperative ultrasound (iUS) is variably used to delineate neuroanatomical structures, enhancing the precision of glioma resections.[58.1]
The evolution of treatment approaches has also been significantly influenced by advancements in understanding the genetic mutations associated with gliomas. The introduction of molecular profiling in glioma classification by the World Health Organization in 2016 has allowed for a more nuanced approach to treatment, integrating molecular characteristics with histopathological criteria.[62.1] This shift has led to the identification of oncogenic gene fusions and mutations, such as IDH and BRAF, which serve as potential therapeutic targets and prognostic indicators.[60.1] Targeted therapies, including IDH inhibitors and BRAF/MEK inhibitors, are currently under investigation and represent a promising avenue for personalized treatment options.[67.1]
Furthermore, recent advancements in molecularly targeted therapies and immunotherapies have transformed the care of patients with malignant gliomas. These strategies aim to address the challenges posed by the aggressive nature of gliomas by targeting specific genetic alterations and enhancing therapeutic efficacy.[66.1] The ongoing research into the molecular biology of gliomas, including insights gained from single-cell RNA sequencing, continues to uncover new aspects of tumor behavior and communication, further informing treatment strategies.[69.1]
Symptoms And Diagnosis
Common Symptoms
The symptoms of glioma can vary significantly depending on the tumor's type, location, and growth rate. Commonly reported symptoms include headaches, which are experienced by approximately half of glioma patients, particularly those with glioblastoma, who may suffer from severe headaches that are often worse in the morning.[106.1] Seizures are another prevalent symptom, especially in cases of astrocytoma, and can manifest as an early sign of the condition.[108.1]
Other frequent symptoms include nausea and vomiting, which may occur alongside cognitive changes such as confusion or memory loss.[105.1] Patients may also experience difficulties with speech, weakness or numbness in the limbs, and alterations in mood or personality.[93.1] Vision changes, including loss of vision, can also be indicative of glioma, as the tumor may exert pressure on surrounding brain structures.[108.1]
The specific symptoms experienced by an individual can be influenced by the glioma's location within the brain or spinal cord, as well as its size and growth dynamics.[105.1] For instance, tumors located in areas responsible for motor function may lead to weakness in specific limbs, while those affecting cognitive areas may result in significant changes in mental function.[91.1] Overall, the diverse range of symptoms underscores the complexity of gliomas and the necessity for thorough diagnostic evaluations, including neurological examinations and imaging studies, to accurately identify and manage the condition.[96.1]
Diagnostic Methods
Advanced neuroimaging techniques play a crucial role in the diagnosis and management of gliomas, the most prevalent primary brain tumors. Among these techniques, magnetic resonance imaging (MRI) has established itself as the gold standard for identifying gliomas and assessing their extent. Detailed imaging provided by MRI is essential for pinpointing tumor borders, which informs surgical approaches and techniques.[116.1] However, conventional MRI often lacks the physiological detail necessary for effective clinical decision-making, highlighting the need for more advanced imaging modalities.[118.1]
Recent advancements in MRI, including diffusion-weighted imaging and perfusion MRI, have significantly enhanced the ability to predict glioma malignancy and understand tumor behavior.[119.1] These modern MRI techniques are pivotal in diagnosing gliomas, as they can noninvasively assess the genetic profile of tumors, which influences their metabolic pathways and cell behavior.[100.1] Furthermore, the integration of artificial intelligence (AI) with multimodal MRI data is anticipated to usher in a new era of precision in glioma diagnosis and therapy, leading to increasingly personalized treatment strategies.[101.1]
Diffusion-tensor imaging (DTI), a functional imaging technology based on diffusion-weighted imaging, allows for a comprehensive evaluation of the diffusion movement of water molecules. This technique provides insights into the degree of compression, infiltration, and destruction of surrounding white matter fiber bundles, which is critical for understanding the tumor's impact on adjacent brain structures.[102.1] Additionally, resting state fMRI (rs-fMRI) is increasingly utilized to analyze spontaneous fluctuations in blood-oxygenated-level-dependent (BOLD) signals, further enhancing the diagnostic capabilities for gliomas.[103.1]
Despite these advancements, the diagnostic accuracy of imaging techniques to delineate gliomas has not been systematically addressed. A meta-analysis has sought to estimate and compare the diagnostic accuracies of conventional imaging techniques and advanced MRI and PET imaging for newly diagnosed diffuse gliomas.[115.1] The findings suggest that while conventional imaging provides useful structural information, it is often insufficient for reliable differentiation between low-grade and high-grade gliomas, underscoring the importance of integrating advanced imaging techniques into clinical practice.[118.1]
Treatment Options
Surgical Interventions
Surgical interventions for glioma treatment have evolved significantly, focusing on maximizing tumor removal while minimizing surgical morbidity and postoperative neurological deficits. The primary objectives of low-grade glioma (LGG) surgery are to achieve maximal tumor resection and to reduce the risks associated with the procedure.[137.1] Recent advancements in surgical tools and techniques, such as intra-operative imaging, fluorescent agents, and functional imaging sequences, have enhanced the ability to identify tumor borders and critical brain areas, thereby improving the rates of complete resections.[136.1]
The decision-making process regarding the extent of tumor resection is influenced by several factors, including the resectability of the tumor, which is determined by its characteristics and location.[154.1] Surgeons must assess whether a gross total resection (GTR) is feasible, or if a partial resection or biopsy is more appropriate. The aim of resection is not only to alleviate mass effect but also to obtain brain tissue for pathological analysis, which is crucial for determining the appropriate treatment plan.[155.1]
Intraoperative techniques, such as neuronavigation and intraoperative MRI, have been shown to improve the extent of resection and subsequently enhance patient outcomes. A systematic review indicated that the use of intraoperative MRI correlates with improved quality of life and survival rates in glioma patients.[155.1] Furthermore, studies have demonstrated that achieving at least 90% extent of resection (EOR) is associated with significantly better overall survival rates, with patients reaching a 5-year overall survival (OS) of 97% compared to 76% for those with less than 90% EOR.[139.1]
Despite these advancements, the risks associated with surgical interventions remain a concern. Treatment-associated morbidity can be moderate, and factors such as patient age and performance status are critical predictors of survival outcomes.[156.1] As the field progresses, the balance between the benefits of aggressive tumor resection and the potential risks continues to be a subject of ongoing research and evaluation.[156.1]
Adjuvant Therapies (Radiation and Chemotherapy)
Adjuvant therapies for glioma, particularly radiation and chemotherapy, play a crucial role in the management of this type of brain tumor. Following initial treatment, which often includes surgery, adjuvant therapies are employed to target residual tumor cells and reduce the risk of recurrence.
Radiation therapy is commonly recommended after surgery, especially for high-grade gliomas, to eliminate remaining cancer cells and improve overall survival rates. The standard approach typically involves conventionally fractionated radiation therapy, delivering a total dose of approximately 60 Gy in 2-Gy fractions.[158.1] Recent advancements in radiation techniques, such as hypofractionated proton beam therapy, have shown promise in improving outcomes for patients, particularly those over the age of 65 with newly diagnosed glioblastoma.[146.1] Additionally, innovative methods like proton-minibeam radiation therapy (pMBRT) are being explored, which may enhance dose distribution and minimize damage to surrounding healthy tissue.[148.1]
Chemotherapy is another critical component of adjuvant treatment for gliomas. The choice of chemotherapy agents often depends on the molecular characteristics of the tumor, including specific genetic mutations. For instance, targeted therapies such as IDH inhibitors and BRAF/MEK inhibitors have emerged as effective options for gliomas with corresponding mutations, potentially offering more personalized treatment strategies.[150.1] The integration of molecular testing into treatment planning allows for a tailored approach, enhancing the therapeutic ratio of conventional and experimental therapies.[151.1]
Recent Advancements
Molecular Characterization and Targeted Therapies
Recent advancements in molecular characterization have significantly influenced the development of targeted therapies for gliomas. The integration of high-throughput Next Generation Sequencing (NGS) has enhanced the understanding of the molecular pathogenesis of high-grade gliomas, allowing for the identification of genetic alterations that can direct personalized cancer treatments for patients with these tumors.[192.1] This progress has been pivotal in informing diagnostic classifications and targeted treatment strategies, thereby facilitating personalized medicine approaches in neuro-oncology.[193.1]
Moreover, the role of molecular profiling has become integral to the 2021 WHO classification of gliomas, underscoring its importance in the treatment landscape.[194.1] Despite the challenges posed by the blood-brain barrier and tumor heterogeneity, advancements in molecular profiling have opened new avenues for investigating glioma mechanisms and therapies.[195.1] These developments are crucial for the validation of biomarkers that can aid in treatment decisions, ultimately allowing for more tailored therapeutic strategies.[193.1]
In addition to molecular profiling, the emergence of molecular targeted therapies and immunotherapies has marked a significant breakthrough in glioma treatment. These therapies are a result of advances in tumor molecular biology and molecular immunology, which have paved the way for precision treatment approaches.[173.1] Promising agents such as Zotiraciclib and Lerapolturev are currently being explored within the context of immunotherapy, highlighting the potential for these strategies to improve patient outcomes.[174.1]
The future of glioma treatment is increasingly leaning towards personalized medicine, which aims to tailor therapeutics to individual patients based on their unique genomic profiles.[203.1] This approach not only maximizes therapeutic efficacy but also addresses the evolving molecular targets present in malignant glioblastoma cells.[203.1] As research continues to progress, the combination of molecular characterization and targeted therapies holds great promise for enhancing treatment efficacy and improving survival rates for glioma patients.
Epidemiology And Risk Factors
Incidence and Demographics
Gliomas represent the most common type of primary intracranial tumors, with diffuse gliomas being the predominant malignant brain tumors in adults. The epidemiology of gliomas, including their incidence and mortality rates, has been the subject of extensive research, revealing significant trends over time. Notably, the incidence of gliomas did not change significantly from 1975 to 2018, with an average annual percentage change (APC) of 0.0% during this period; however, a significant increase in incidence was observed from 1975 to 1987.[221.1]
Demographic studies have highlighted variations in glioma incidence by subtype and age. For instance, research conducted in the United States from 1992 to 2007 indicated that different glioma subtypes, such as astrocytomas and oligodendrogliomas, exhibited distinct demographic trends.[223.1] Furthermore, a significant decline in glioma incidence and mortality rates was noted from 1987 to 2018, particularly in non-glioblastoma astrocytomas, which contributed most to the overall trends.[224.1]
The analysis of glioma incidence data from the SEER-9 incidence database, which encompasses cases from nine high-quality registries covering approximately 9.4% of the U.S. population, provides a comprehensive overview of these trends.[227.1] This data indicates that while the overall incidence remained stable, specific demographic factors, including age and calendar period, may influence the incidence rates of different glioma subtypes.[226.1]
Environmental and Genetic Risk Factors
Gliomas are influenced by a combination of environmental and genetic risk factors. Among the environmental factors, exposure to ionizing radiation is the only well-established risk factor for glioma development. This association is particularly evident in patients who have received high-dose radiotherapy for other cancers during childhood, as well as in those exposed to low-dose cranial and cervical irradiation for conditions such as tinea capitis.[245.1] Despite the established link with ionizing radiation, the overall incidence of gliomas remains low, and the role of other environmental exposures has been less thoroughly investigated.[248.1]
In addition to ionizing radiation, certain lifestyle and occupational exposures may also contribute to glioma risk. Analytic epidemiologic studies have sought to identify potential risk factors by comparing individuals with and without glioblastoma, focusing on various characteristics, including environmental and occupational exposures.[247.1] However, the evidence regarding these additional environmental factors remains inconclusive, necessitating further research to clarify their roles in glioma etiology.[248.1]
Genetic factors also play a significant role in glioma risk. Approximately 25% of the variance in glioma incidence can be attributed to genetic factors, with only a portion of this explained by currently identified genetic variants.[220.1] While most gliomas develop without a family history, certain inherited genetic variations have been linked to increased susceptibility. For instance, rare genetic syndromes such as Li-Fraumeni syndrome, associated with TP53 mutations, and neurofibromatosis types 1 and 2 are known to contribute to glioma risk.[239.1] Genome-wide association studies have identified numerous single nucleotide polymorphisms (SNPs) that are associated with glioma, with some variants significantly increasing the relative risk of developing specific types of gliomas.[240.1]
Prognostic Factors
Clinical Characteristics
The clinical characteristics of gliomas are critical in determining prognosis and guiding treatment decisions. Histopathological analysis remains a cornerstone in the diagnosis and classification of gliomas, with the World Health Organization (WHO) tumor grade being the most established prognostic factor. This grading system assesses tumor aggressiveness and its resemblance to normal brain tissue, which is essential for predicting patient outcomes and tailoring treatment strategies.[273.1]
Molecular factors have increasingly been recognized as significant prognostic indicators. Key molecular markers include isocitrate dehydrogenase (IDH) status and 1p/19q co-deletion, which have been shown to influence survival outcomes in glioma patients. IDH mutations are particularly important, as they correlate with better prognoses in glioma patients, especially when combined with extensive surgical resection.[276.1] Additionally, the presence of CDKN2A deletions has been associated with shorter progression-free survival (PFS) and overall survival (OS) in both lower-grade and high-grade gliomas.[264.1]
Age is another critical factor influencing prognosis. Younger patients generally have better outcomes, while older patients (aged 60 years and above) are at a higher risk for poor prognosis.[270.1] The relationship between age and prognosis is complex and non-linear, suggesting that treatment decisions should be individualized based on precise age considerations.[267.1] Furthermore, clinical parameters such as the Karnofsky Performance Status (KPS) and the extent of surgical resection also play vital roles in prognostication. Low preoperative KPS scores and partial tumor resection are associated with worse survival outcomes.[271.1]
Molecular Markers
Molecular markers have become increasingly significant in the prognostication and treatment of gliomas, particularly following the 2016 update to the World Health Organization (WHO) classification system, which integrated molecular profiles into glioma classification. This shift has prompted extensive research into the utility of molecular signatures for predicting prognosis and therapeutic responses in glioma patients.[279.1] Among the most notable molecular prognostic factors are mutations in the IDH1 and IDH2 genes, as well as the methylation status of the MGMT promoter. These factors have been identified as promising biomarkers that can significantly influence survival outcomes in patients with glioblastoma (GBM).[280.1]
The presence of IDH mutations, particularly IDH1, is associated with a better prognosis and has been shown to affect the tumor's biological behavior, including its response to chemotherapy.[297.1] Specifically, IDH1 mutations lead to cell cycle arrest and increased sensitivity to chemotherapy, which may explain the improved survival rates observed in patients with these mutations compared to those with wild-type IDH1.[297.1] Furthermore, the classification of gliomas now relies heavily on the identification of these mutations and the presence of 1p/19q co-deletions, which are essential for accurate diagnosis and treatment planning.[296.1]
In addition to IDH mutations, the methylation status of the MGMT promoter is another critical factor that influences treatment decisions. Methylation of the MGMT promoter is associated with a favorable response to alkylating agents, making it a vital consideration in the development of personalized treatment plans for glioma patients.[280.1] The integration of these molecular markers into clinical practice aims to enhance the personalization of treatment strategies, allowing for more tailored therapeutic approaches based on individual tumor characteristics.[282.1]
Despite the promising potential of molecular biomarkers, several challenges remain in their integration into routine clinical practice. One significant obstacle is the high degree of intratumoral heterogeneity, which can result in varying genetic and molecular profiles within the same tumor.[283.1] This complexity complicates the application of molecular markers in clinical settings and highlights the need for ongoing research to refine prognostic models and improve treatment outcomes for glioma patients.[281.1]
Challenges In Treatment
Treatment Resistance
Glioblastoma (GBM), classified as a Grade 4 glioma by the World Health Organization (WHO), presents significant treatment resistance due to its aggressive and invasive nature, rapid growth, and inherent resistance to conventional therapies such as chemotherapy and radiation.[304.1] Approximately 80%-85% of malignant brain tumors in adults are gliomas, with GBM being the most prevalent and lethal form.[305.1] The diffuse invasion characteristic of GBM allows the tumor to evade complete surgical resection and diminishes the efficacy of chemoradiation therapy.[306.1]
The resistance mechanisms in GBM are multifaceted. One major factor is the unique biology of GBM cells, which can evade the effects of standard treatments through increased resistance to cell death and the presence of genetically unstable and heterogeneous cell populations.[327.1] Additionally, GBM tumors often exhibit amplified expression of the epithelial growth factor receptor (EGFR), which enhances cell proliferation via the receptor tyrosine kinase/Ras/PI3K/AKT signaling pathway, further complicating treatment efforts.[307.1]
Moreover, the complex microenvironment of GBM contributes to therapeutic resistance, characterized by immune evasion, tumor repopulation by stem cells, and limited drug penetration across the blood-brain barrier (BBB).[309.1] This environment not only protects the tumor from immune responses but also hinders the effectiveness of systemic therapies.[313.1]
Recent advancements in nanotechnology have introduced innovative strategies aimed at overcoming these challenges. Engineered nanomaterials (ENMs) are being explored for their potential to enhance drug delivery specifically to glioma cells, thereby improving treatment outcomes.[320.1] However, the integration of these novel approaches into clinical practice remains challenging due to the need for effective targeting and the complexities of the tumor microenvironment.[315.1]
Future Directions
Emerging Research Areas
Emerging research areas in glioma treatment are increasingly focusing on the integration of novel therapeutic strategies and advanced technologies. One significant area of exploration is the use of immunotherapy, which includes approaches such as immune checkpoint blockade, chimeric antigen receptor T (CAR T) cell therapy, oncolytic virotherapy, and vaccine therapy. These strategies have shown promise in improving outcomes for glioblastoma (GBM) patients, with ongoing studies investigating combinatorial therapies aimed at enhancing antitumor immune responses while minimizing adverse side effects.[349.1]
Additionally, the complex microenvironment of GBM presents substantial challenges to effective therapy, primarily due to factors such as immune evasion and limited drug penetration across the blood-brain barrier (BBB).[350.1] To address these challenges, recent advancements in nanocarrier-based drug delivery systems are being emphasized. These include innovative drug delivery methods utilizing liposomes, nanoparticles, and dendrimers, which are currently under investigation in clinical trials.[350.1]
Another promising area of research involves the application of CRISPR/Cas9 gene-editing technology. This tool is being utilized to enhance our understanding of glioma biology, facilitate the establishment of tumor models, and screen for targeted therapies. Specifically, CRISPR/Cas9 has been employed to knock out genes associated with glioma cell survival and resistance to treatments such as temozolomide (TMZ), thereby providing insights into potential therapeutic targets.[380.1] The technology is also being explored for its role in immunotherapy, with studies indicating its potential to advance gene research and engineering strategies in glioma therapy.[378.1]
Potential Innovations in Therapy
Integration of genome-wide data from various technologies has significantly advanced the identification of potential protein targets in glioma, enhancing the reliability and biological interpretability of results. This integration includes multi-omics data, such as genomics, transcriptomics, proteomics, and pathomics, which, when combined with radiomics, improves the understanding of the biological significance of radiomic features and enhances the prediction of genetic mutations, prognosis, and treatment response in glioma patients.[352.1] Furthermore, the identification of oncogenic gene fusions in diffuse gliomas has emerged as a potential therapeutic target and prognostic indicator, representing a novel strategy for personalized medicine in glioma treatment.[353.1]
Despite these advancements, challenges remain in implementing personalized medicine based on genetic markers due to the heterogeneous genetic background of tumor cells, which is further complicated by epigenetic changes. These factors create obstacles for the detection, characterization, and treatment of glioblastomas, yet they also present opportunities for developing advanced diagnostic modalities and individualized therapies.[354.1]
In terms of therapeutic innovations, nanoparticle technology has shown promise in targeting glioma cells more effectively than traditional treatment methods. Various classes of nanoparticles have been developed for glioma treatment, offering advantages such as multifunctionality, effective drug transport, and regulated drug cargo release.[358.1] Notably, nanoparticles can exploit biological pathways to achieve specific delivery to cellular and intracellular targets, including the ability to cross the blood-brain barrier, which many anticancer drugs cannot.[359.1] Recent studies have demonstrated the efficacy of bioadhesive nanoparticles that adhere to tumor sites and release therapeutic agents slowly, enhancing treatment outcomes for glioblastoma.[357.1]
Moreover, a combinatorial, personalized approach to therapy is gaining traction, integrating standard care methods such as surgery, radiation, and chemotherapy with active immunotherapy and multiagent targeting of immunosuppressive checkpoints.[360.1] Immunotherapy strategies, including immune checkpoint inhibitors, adoptive T-cell therapies, tumor vaccines, and oncolytic viral therapies, are being explored to improve treatment outcomes in glioblastoma.[364.1] Trials involving dendritic cell vaccines targeting specific antigens have shown promising results, indicating a potential shift towards more effective immunotherapeutic strategies in glioma treatment.[363.1]
References
60
eurjmedres.biomedcentral.com
118
pubmed.ncbi.nlm.nih.gov
146
cancerblog.mayoclinic.org
313
pubmed.ncbi.nlm.nih.gov
353
eurjmedres.biomedcentral.com